Patents by Inventor Stéphanie Liénart

Stéphanie Liénart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GARP-TGF-BETA ANTIBODIES
    Publication number: 20210324061
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: November 12, 2020
    Publication date: October 21, 2021
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • Nucleic acids encoding GARP-TGF-beta 1 antibodies
    Patent number: 10875914
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: December 29, 2020
    Assignees: argenx BVBA, Université Catholique de Louvain
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stëphanie Liénart, Sophie Lucas, Pierre Coulie
  • Method of screening for anti-GARP antibodies
    Patent number: 10822424
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 3, 2020
    Assignee: Université catholique de Louvain
    Inventors: Sophie Lucas, Stéphanie Lienart, Pierre Coulie
  • GARP-TGF-? 1 IGG antibodies
    Patent number: 10793627
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: October 6, 2020
    Assignees: argenx BVBA, Université Catholique de Louvain
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • GARP-TGF-BETA 1 ANTIBODIES
    Publication number: 20200095311
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 26, 2020
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • ANTI-GARP PROTEIN AND USES THEREOF
    Publication number: 20200087404
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Application
    Filed: March 29, 2019
    Publication date: March 19, 2020
    Inventors: Sophie Lucas, Stéphanie Lienart
  • GARP-TGF-BETA 1 ANTIBODIES
    Publication number: 20190375832
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: May 10, 2019
    Publication date: December 12, 2019
    Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • GARP-TGF-beta 1 antibodies
    Patent number: 10479829
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 19, 2019
    Assignees: argenx BVBA, Université Catholique de Louvian
    Inventors: Sebastian Van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
  • GARP-TGF-BETA ANTIBODIES
    Publication number: 20180327487
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 15, 2018
    Inventors: Sebastian Van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Federica Linty, Gitte De Boeck, Hans De Haard, Stéphanie Liénart, Sophie Lucas, Pierre Coulie, Michael Saunders